Telluride Asset Management’s Crescent Biopharma CBIO Stock Holding History

Telluride Asset Management’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	$113K	Buy	+134	New	+$133K	0.1%	228

Other funds holding CBIO

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

WSA

Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MSA

Mason Street Advisors Milwaukee, Wisconsin $1.02B AUM 8.35% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Telluride Asset Management's CBIO Position: Q2 2014 in Review

Telluride Asset Management opened a new position in Crescent Biopharma (CBIO) in Q2 2014: 134 shares worth $113K. The stake represents 0.1% of the portfolio and ranks #228 among its holdings.

32 funds tracked by Wall St. Rank hold CBIO as of Q2 2014.

Telluride Asset Management held 134 shares of Crescent Biopharma worth $113K as of Q2 2014.
Crescent Biopharma was a new Telluride Asset Management position in Q2 2014.
Crescent Biopharma made up 0.1% of Telluride Asset Management's portfolio in Q2 2014, its #228 holding.
32 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2014.

Based on Telluride Asset Management's 13F filing for Q2 2014, filed 14 Aug 2014.